Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

(RTTNews) - Alumis Inc. (ALMS) announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

Alumis brings to the table its precision approach to clinical outcomes, with its most advanced product candidate, ESK-001, an oral inhibitor for plaque psoriasis and systemic lupus erythematosus ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus Phase 2 OLE data of ESK ...